Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 2 November 2021, 16:30 HKT/SGT
Share:
    

Source: JSP Pharmaceutical Manufacturing (Thailand) PCL
JSP Pharmaceutical Manufacturing (SET: JP) debuts shares on MAI
Aims to be leader in R&D, production and distribution of medicines and nutritional supplements

BANGKOK, Nov 2, 2021 - (ACN Newswire) - JSP Pharmaceutical Manufacturing (Thailand) PCL (SET: JP), a developer, manufacturer and distributor of modern and traditional medicines, herbal products and nutritional supplements, is debuting on the MAI today. JSP is ready to pursue growth through developing new products under own brands, aiming for higher profit margins by boosting own brand sales to 50% of total sales of all products, while increasing capacity, improving capital management efficiency, expanding OEM production, and ultimately leading in the R&D, production and distribution of medicines and nutritional supplements.

Dr. Sittichai Daengprasert, Chief Executive Officer of JSP Pharmaceutical Manufacturing (Thailand) PCL, whose shares will begin trading on the SET Market of Alternative Investment (MAI) today in the Consumer Products sector under the symbol JP, says it is a crucial step for the company to pursue sustainable growth in order to become a leader in the R&D, manufacture and distribution of medicinal and nutritional supplement products in Thailand. It plans to drive growth with innovations in the development of modern and traditional medicines, and herbal and nutritional supplement products to satisfy consumers' demand for high-quality products for health maintenance, protection and treatment. The plan will lend support to Thailand's effort to become a society of health care in the near future.

Dr. Sittichai says the proceeds from the IPO share sales will go toward the development of new health products under the company's own brands with a goal to produce 4-5 new products each year. Meanwhile, a multi-channel marketing strategy will be employed for product distribution, encompassing pharmacies, modern trade stores, convenience stores, TV home shopping, and online channels. The aim is to boost sales of own-brand products to 50% of total sales, which will contribute positively to the gross profit in the future.

Plans to improve the efficiency of the Bangkok plant, a hub of modern medicine production, and expand the capacity of the plant in Lamphun, which produces traditional medicines and nutritional supplements, will support the expansion of the OEM customer base in Thailand and in the CLMV countries with a one-stop service. Equipped with a list of more than 2,000 registered medicines, JP is in an advantageous position to meet OEM customers' demands, Dr. Sittichai says.

He adds that the company has also been cooperating with educational institutes, government agencies and private-sector parties in the development and processing of herbs, such as Wolffia globosa, as a plant-based protein supplement under the 'Suphap Osot' brand to add value to agricultural products. In this program, cultivation know-how is transferred to farmers as a way to help them earn increased income. Furthermore, JP is preparing its manufacturing base to produce extracts from cannabis and hemp. These extracts are to be sold as processed products or used as ingredients in health products under the company's own brands.

Mr. Vorachart Tuaychareon, Managing Director of Finnex Advisory Co., Ltd., a financial advisor, says JP's potential for growth looks bright amid positive factors resulting from increasing demands for modern and herbal medicines from health-conscious consumers while the government sector encourages people to consume locally-made medicinal products. The company's extensive experience and expertise in the R&D of diverse medicinal products and its experienced executives' ceaseless pursuit of business opportunities are sure to improve its competitiveness and growth prospects.

Mr. Chosit Detwanitchayanumut, Managing Director of Siam Alpha Capital Co., Ltd., a joint financial advisor, says JP is determined to strengthen its operations in all respects by highlighting product innovations and investing in marketing campaigns to increase public awareness of its own brands as well as expand its OEM customer base both here and abroad. The company's strong fundamentals lend firm support for its drive toward a sustainable growth, he adds.

Mr. Chanachai Joonjiraporn, Chief Executive Officer, ASL Securities Co., Ltd., the lead underwriter, says JP's shares are growth stock because of the strength of its operations. Its commitment to pursue long-term and sustainable growth lays a firm foundation on which its shares are grounded and is the reason that will attract sustained investors' interest in JP's shares.

Released by Public Relations Dept., MT Multimedia Co. Ltd.
for JSP Pharmaceutical Manufacturing (Thailand) PCL
For more information, please contact: Yuttachai Praikhanahok (Tle)
Tel: +66-91-736-2866 or +66-2-612-2081 ext 125
Email: yuttachai.p@mtmultimedia.com


Topic: IPO
Source: JSP Pharmaceutical Manufacturing (Thailand) PCL

Sectors: Daily Finance, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving  
Dec 19, 2025 10:30 HKT/SGT
Air T, Inc. Announces Closing of Regional Express Acquisition  
Dec 19, 2025 06:10 HKT/SGT
MHI Participates in Demonstration Testing of Vehicle-Infrastructure Integration System for Autonomous Buses in Shimotsuke City  
Friday, December 19, 2025 2:24:00 AM
NEC and emaratech Collaborate on Biometric Smart Gates Supporting UAE Airport Operations  
Friday, December 19, 2025 2:06:00 AM
Fujitsu to showcase mobility and physical AI tech at CES 2026  
Friday, December 19, 2025 1:42:00 AM
Kirin and Fujitsu elucidate a novel gut-brain axis mechanism of citicoline for the first time worldwide through AI-based analysis and experimental validation leveraging drug discovery DX technology  
Friday, December 19, 2025 1:06:00 AM
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Released Their Fourth Collaborative Musical Work with Sound Wellness Lab (Della): "Precious Metal Orchestra - A Musical Voyage through the Sound of Precious Metals for Christmas" now available for streaming.  
Thursday, December 18, 2025 9:00:00 PM
Focus Graphite Announces Final Results From 2022 Drill Program at Lac Tetepisca; West Limb Extends Mineralized Strike to 8 KM  
Dec 18, 2025 18:09 HKT/SGT
Spritzer MerryLand Returns This Year-End, Bringing Magical Festive Cheer to Taiping  
Dec 18, 2025 17:44 HKT/SGT
PropertyGuru Asia Real Estate Summit spotlights PropertyGuru Week 2025 with conversations on 'Trusted Marketplaces and Thriving Communities'  
Thursday, December 18, 2025 9:00:00 AM
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: